鶹Ů

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 鶹Ů Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Feb 12 2024

Full Issue

Generics Drugmaker Aurobindo Cuts Production Over Safety Problems

A key facility in India has seen some of its production cut after U.S. inspectors found manufacturing problems — highlighting drug-quality issues even during an ongoing medicines shortage. Also in the news: Weight loss drug manufacturers are trying to tackle supply issues.

Aurobindo, which is one of the largest generic drug makers, has halted some production at a key facility in India after U.S. inspectors found manufacturing problems, the latest such episode to underscore concerns over both shortages and the quality of medicines produced by some suppliers. (Silverman, 2/9)

The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said supply woes likely won’t go away anytime soon, as the popularity of those medicines continues to soar. But both companies are showing encouraging progress in their efforts to increase supply. (Constantino, 2/10)

Novo Nordisk said Friday it settled two lawsuits against two businesses claiming to offer compounded versions of its blockbuster drugs Ozempic and Wegovy. The drugmaker has filed a total of 12 lawsuits against clinics, med spas and compounding pharmacies in the U.S. that claim to offer semaglutide, the active ingredient in Ozempic and Wegovy. Novo Nordisk holds the patent on semaglutide, and the drugmaker does not supply the ingredient to outside groups, leaving some experts wondering what exactly is being sold to consumers. (Lovelace Jr., 2/9)

Efforts in Congress to restrict U.S. market access for Chinese biotech companies and investors face a central dilemma: They could disrupt key relationships and supply chains U.S. life sciences companies rely on. (Snyder, 2/12)

Pfizer has touched down at the Super Bowl. The Big Pharma ran its “Here’s to Science” ad at the event, framing its work to “outdo cancer” as part of a history of breakthroughs dating back to Hippocrates. In the 60-second ad, which also comes in an extended 90-second cut, Pfizer shows paintings, statues and photos of people such as Isaac Newton, its founders Charles Erhart and Charles Pfizer, Galileo and Albert Einstein singing along to Queen’s Don't Stop Me Now. Pfizer’s chief marketing officer Drew Panayiotou discussed the decision to show the ad at the Super Bowl in an accompanying behind the scenes video. (Pfizer, 2/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 鶹Ů